MX2018009228A - Proteínas de unión a antigeno que se unen a pd-l1. - Google Patents

Proteínas de unión a antigeno que se unen a pd-l1.

Info

Publication number
MX2018009228A
MX2018009228A MX2018009228A MX2018009228A MX2018009228A MX 2018009228 A MX2018009228 A MX 2018009228A MX 2018009228 A MX2018009228 A MX 2018009228A MX 2018009228 A MX2018009228 A MX 2018009228A MX 2018009228 A MX2018009228 A MX 2018009228A
Authority
MX
Mexico
Prior art keywords
bind
antigen binding
binding proteins
manufactured
higher yields
Prior art date
Application number
MX2018009228A
Other languages
English (en)
Inventor
Zhou Heyue
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2018009228A publication Critical patent/MX2018009228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan anticuerpos anti-PD-L1 de clase igG que tienen una mejor capacidad para elaborarse con altos rendimientos. Más específicamente, se divulgan anticuerpos humanos que se unen a PD-L1, fragmentos de unión a PD-L1 que se pueden elaborar con altos niveles.
MX2018009228A 2016-01-29 2017-01-27 Proteínas de unión a antigeno que se unen a pd-l1. MX2018009228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29
PCT/US2017/015429 WO2017132562A1 (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Publications (1)

Publication Number Publication Date
MX2018009228A true MX2018009228A (es) 2019-07-08

Family

ID=59386438

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009228A MX2018009228A (es) 2016-01-29 2017-01-27 Proteínas de unión a antigeno que se unen a pd-l1.
MX2022011659A MX2022011659A (es) 2016-01-29 2018-07-27 Proteinas de union a antigeno que se unen a pd-l1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011659A MX2022011659A (es) 2016-01-29 2018-07-27 Proteinas de union a antigeno que se unen a pd-l1.

Country Status (16)

Country Link
US (4) US10118963B2 (es)
EP (1) EP3408400B1 (es)
JP (3) JP6883590B2 (es)
KR (1) KR20190026642A (es)
CN (2) CN109715821B (es)
AU (1) AU2017212717B2 (es)
BR (1) BR112018015480A2 (es)
CA (1) CA3013051A1 (es)
CL (1) CL2018002034A1 (es)
EA (1) EA037855B1 (es)
IL (1) IL260846B2 (es)
MX (2) MX2018009228A (es)
PH (1) PH12018501611A1 (es)
SG (1) SG11201806496SA (es)
TW (1) TWI760323B (es)
WO (1) WO2017132562A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084444A (ko) * 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10118963B2 (en) 2016-01-29 2018-11-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2019237212A1 (en) * 2018-03-22 2020-09-24 Keires Ag Antagonistic PD-1, PD-L1 and LAG-3 binding proteins
EP3778635A4 (en) 2018-04-09 2022-01-26 Origincell Therapeutics Co., Ltd. ANTI-PD-L1 ANTIBODIES AND ITS USE
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN116063519A (zh) * 2018-08-20 2023-05-05 北京强新生物科技有限公司 新型癌症免疫治疗抗体组合物
JP2022529269A (ja) * 2019-04-18 2022-06-20 キューエルエスエフ バイオセラピューティック インコーポレイテッド ヒト化抗ｐｄ－ｌ１抗体
JP2022521958A (ja) * 2019-08-29 2022-04-13 榮昌生物制薬（烟台）股▲フン▼有限公司 抗ｐｄ－ｌ１抗体及びその応用
US20230338574A1 (en) 2020-09-02 2023-10-26 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same
EP4245865A1 (en) 2020-11-16 2023-09-20 Immuneoncia Therapeutics, Inc. Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof
EP4335872A1 (en) 2021-05-07 2024-03-13 Immuneoncia Therapeutics, Inc. Bispecific antibody specifically binding to cd47 and pd-l1
CA3221925A1 (en) 2021-06-09 2022-12-15 Sorrento Therapeutics, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
WO2024064640A2 (en) * 2022-09-19 2024-03-28 Sonoma Biotherapeutics, Inc. Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
EP1170300A1 (en) 1992-07-13 2002-01-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US8222214B2 (en) 2007-06-01 2012-07-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA2913977C (en) * 2013-05-31 2022-11-29 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US10267806B2 (en) 2014-04-04 2019-04-23 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
US10118963B2 (en) * 2016-01-29 2018-11-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1

Also Published As

Publication number Publication date
EA037855B1 (ru) 2021-05-27
BR112018015480A2 (pt) 2019-05-21
JP2022095910A (ja) 2022-06-28
JP2021102633A (ja) 2021-07-15
WO2017132562A8 (en) 2017-09-08
CN116333124A (zh) 2023-06-27
CL2018002034A1 (es) 2019-03-15
WO2017132562A1 (en) 2017-08-03
SG11201806496SA (en) 2018-08-30
EP3408400A4 (en) 2019-11-27
US10118963B2 (en) 2018-11-06
MX2022011659A (es) 2022-10-13
EP3408400A1 (en) 2018-12-05
US10919964B2 (en) 2021-02-16
CN109715821A (zh) 2019-05-03
IL260846B (en) 2022-10-01
EP3408400B1 (en) 2024-06-26
CA3013051A1 (en) 2017-08-03
TW201736400A (zh) 2017-10-16
JP6883590B2 (ja) 2021-06-09
JP7140867B2 (ja) 2022-09-21
US20170218066A1 (en) 2017-08-03
EA201891709A1 (ru) 2019-01-31
JP2019507183A (ja) 2019-03-14
AU2017212717A1 (en) 2018-09-06
CN109715821B (zh) 2022-09-06
AU2017212717B2 (en) 2023-11-16
US20190092861A1 (en) 2019-03-28
US11919952B2 (en) 2024-03-05
KR20190026642A (ko) 2019-03-13
PH12018501611A1 (en) 2019-04-08
TWI760323B (zh) 2022-04-11
IL260846A (es) 2018-09-20
IL260846B2 (en) 2023-02-01
US20210147539A1 (en) 2021-05-20
US20240190959A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EP3786183A3 (en) Antigen binding constructs to cd3
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
SG10201806108TA (en) Binding proteins and methods of use thereof
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
BR112018068678A2 (pt) anticorpos anti-mica
MX2015012540A (es) Ratón de cadena ligera común.
AU2015347015A8 (en) Antibody drug conjugates
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
EA201500502A1 (ru) Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof